Discounted Cash Flow
Ascendis Pharma A/S ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $4.6m | $-68.7m | $-60.2m | -1492.2% | $-2.58 |
| 2017 | $1.5m (-66.8%) | $-124.4m (-81.0%) | $-95.1m (-58.0%) | -8129.0% (-444.8%) | $-3.68 (-42.6%) |
| 2018 | $10.6m (591.6%) | $-130.5m (-4.9%) | $-138.8m (-46.0%) | -1233.3% (84.8%) | $-3.17 (13.9%) |
| 2019 | $13.4m (26.4%) | $-218.2m (-67.3%) | $-175.9m (-26.8%) | -1631.8% (-32.3%) | $-4.69 (-47.9%) |
| 2020 | $7.0m (-48.0%) | $-419.0m (-92.0%) | $-271.5m (-54.3%) | -6025.5% (-269.3%) | $-8.28 (-76.5%) |
| 2021 | $7.8m (11.9%) | $-383.6m (8.4%) | $-439.3m (-61.8%) | -4931.6% (18.2%) | $-7.00 (15.5%) |
| 2022 | $51.2m (557.9%) | $-583.2m (-52.0%) | $-601.0m (-36.8%) | -1139.6% (76.9%) | $-10.40 (-48.6%) |
| 2023 | $266.7m (421.2%) | $-481.4m (17.4%) | $-467.4m (22.2%) | -180.5% (84.2%) | $-8.55 (17.8%) |
| 2024 | $363.6m (36.3%) | $-378.1m (21.5%) | $-306.2m (34.5%) | -104.0% (42.4%) | $-6.53 (23.6%) |
| 2025 | $720.1m (98.0%) | $-228.0m (39.7%) | $36.5m (111.9%) | -31.7% (69.5%) | $-3.76 (42.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.